Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Terumo Debuts Cell-Based Heart Failure Therapy HeartSheet
May 31, 2016
- Takeda’s Myeloma Drug Hopeful Ninlaro Rebuffed by CHMP
May 31, 2016
- Takeda Gets CHMP’s Positive Opinion for New Adcetris Indication
May 31, 2016
- Mylan Japan Labor Union, Management Reach Settlement; All 14 Members to Leave on May 31
May 30, 2016
- Ethical Drug Sales Up 6.1% in March: Crecon Report
May 30, 2016
- Application Filing Expected in FY2018 for Cancer Peptide Vaccine Originating from Kurume Univ.
May 30, 2016
- Kyorin to Exclusively Market MSD’s Desloratadine in Japan
May 27, 2016
- Astellas Grants Thunderbolt Pharma Rights for BAFF/APRIL Dual Antagonist Program
May 26, 2016
- Eisai Rolls Out AMPA Receptor Antagonist Fycompa
May 26, 2016
- AZ Launches Tagrisso for Treatment of NSCLC
May 26, 2016
- Shionogi’s Naldemedine Delivers Positive Results in Global PIII
May 25, 2016
- Hyperparathyroidism Drug Etelcalcetide Meets Primary Endpoint in Japan PIII: Ono
May 25, 2016
- Toyama Chemical Files Ozex for Mycoplasma Pneumoniae at Request of Academic Societies
May 25, 2016
- Bardoxolone Methyl Improves Renal Function in Japan PII: Kyowa Kirin
May 24, 2016
- PCSK9 Inhibitor Alirocumab Lowers LDL-C in Japanese Diabetes Patients: PIII Sub-Analysis
May 24, 2016
- Japan’s Top 3 Drug Makers Join Forces on Biomarker Research
May 24, 2016
- Repatha Shows Safety, Efficacy in Japanese Patients Regardless of Glycemic Status: Subanalysis Data
May 24, 2016
- Ozawa to Step Down as J-TEC CEO, Fujifilm’s Hiruma to Take Over
May 23, 2016
- Jiangsu Hengrui Medicine Eyes Launch of 2-3 Generics in Japan Every Year: CEO
May 23, 2016
- Generic Makers Enjoy Revenue Rises as Govt Tailwinds Continue: Jiho Tally
May 23, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…